A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2002
10/29/2002	US6472390 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
10/29/2002	US6472385 Compositions and methods to enhance cancer chemotherapy in p53 defective tumors
10/29/2002	US6472379 Angiogenesis inhibition
10/29/2002	US6472218 Routing the set of candidate chemical compounds to one or more automated liquid handlers with the transport pathway, assaying the candidate chemical compounds for pharmacological activity
10/29/2002	US6472195 Human kallikrein
10/29/2002	US6472172 DNA encoding a novel human inhibitor-of-apoptosis protein
10/29/2002	US6472165 Modulatory binding site in potassium channels for screening and finding new active ingredients
10/29/2002	US6472145 A mobile ionophore composition effective to modulate app catabolism without substantially altering the viability of app-containing cells; inhibits amyloid deposition; alzheimer's disease; nontoxic
10/29/2002	US6472140 α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
10/29/2002	US6471998 Chromium picolinate compositions
10/29/2002	US6471997 Antagonist of calcitonin gene related peptide, cgrp and/or of substance p; cosmetic
10/29/2002	US6471987 Ligating band comprises an elastomeric layer and an inner drug releasing layer; chemotherapeutic agent for treating a mucosa, polyp or other growth
10/29/2002	US6471978 Localized use of nitric oxide-adducts to prevent internal tissue damage
10/29/2002	US6471970 Use of pharmaceutical compositions capable of being gelled in periodontology
10/29/2002	US6471969 Two-phase preparation
10/29/2002	US6471957 Canine IL-4 immunoregulatory proteins and uses thereof
10/29/2002	US6471951 Cosmetic waxes or oils having uniform dispersions of insoluble inorganic pigments in carriers
10/29/2002	US6471943 Formulation and method for treating neoplasms by inhalation
10/29/2002	CA2236553C Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy
10/29/2002	CA2215922C Methods for screening compounds for estrogenic activity
10/25/2002	WO2001078652A2 Methods for drug discovery, disease treatment, and diagnosis using metabolomics
10/25/2002	EP1017376A4 Method of treating heart failure
10/25/2002	CA2443806A1 Methods for drug discovery, disease treatment, and diagnosis using metabolomics
10/25/2002	CA2383175A1 Methods and kits for treating depression or preventing deterioration of cognitive function
10/24/2002	WO2002084294A2 Gastrointestinal glutathione peroxidase in hepatitis c virus infections
10/24/2002	WO2002083950A1 Methods and compositions for treating cardiovascular disease using 10218
10/24/2002	WO2002083946A1 Method of examining allergic disease
10/24/2002	WO2002083926A2 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	WO2002083898A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	WO2002083874A2 Endothelial cell expression patterns
10/24/2002	WO2002083873A2 Enzymes
10/24/2002	WO2002083858A2 Methods to inhibit viral replication
10/24/2002	WO2002083847A2 Cdna encoding the human alpha2 delta4 calcium channel subunit
10/24/2002	WO2002083727A2 Nucleic acid sequences of hyperplasies and tumors of the thyroid
10/24/2002	WO2002083712A2 Transporters and ion channels
10/24/2002	WO2002083709A2 Kinases and phosphatases
10/24/2002	WO2002083704A1 Vascular endothelial growth factor 2
10/24/2002	WO2002083674A2 Compositions containing imidazotriazinone for nasal application
10/24/2002	WO2002083669A1 Tropane alkaloid multidrug resistance inhibitors from erythroxylum pervillei and use of the same
10/24/2002	WO2002083655A1 Prodrugs of cox-2 inhibitors
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002083241A1 Single dose aromatase inhibitor for treating infertility
10/24/2002	WO2002083240A1 Aromatase inhibition to enhance assisted reproduction
10/24/2002	WO2002083216A1 Method of intradermally injecting substances
10/24/2002	WO2002083177A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
10/24/2002	WO2002083176A2 Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming
10/24/2002	WO2002083152A1 Activation of natural killer cells by adenosine a3 receptor agonists
10/24/2002	WO2002083134A1 Aryl and biaryl piperidines used as mch antagonists
10/24/2002	WO2002083130A1 Enantiomers of n-[[2'-[[(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-n,3,3-trimethylbutanamide
10/24/2002	WO2002083128A1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
10/24/2002	WO2002083126A1 Phenylindoles for the treatment of hiv
10/24/2002	WO2002083124A1 A composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
10/24/2002	WO2002083123A1 Aurones as telomerase inhibitors
10/24/2002	WO2002083120A2 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
10/24/2002	WO2002083119A1 Pharmaceutical composition comprising ibuprofen and prochlorperazine
10/24/2002	WO2002083116A1 Methods of treating prion disease in mammals comprising administering a chaotropic agent such as guanidine, urea or potassium iodide
10/24/2002	WO2002083115A1 Treatment of disorders secondary to organic impairments
10/24/2002	WO2002083113A2 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
10/24/2002	WO2002083109A1 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
10/24/2002	WO2002083108A2 Compositions containing cgmp pde inhibitors and local anaesthetic agents for nasal application
10/24/2002	WO2002083096A1 Modification of the sustained release profile
10/24/2002	WO2002083088A1 Methods of preventing uvb-induced skin damage
10/24/2002	WO2002083079A2 Aerosol compositions containing formoterol for delivery to the lungs via nebulization
10/24/2002	WO2002083074A2 Methods for the treatment of hepatic disorders
10/24/2002	WO2002083067A2 Prodrugs via acylation with cinnamate
10/24/2002	WO2002083066A2 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
10/24/2002	WO2002083064A2 A method of treating cancer
10/24/2002	WO2002066019A3 Cancer treatment
10/24/2002	WO2002053140A3 New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
10/24/2002	WO2002051848A3 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002047667A3 Novel medicament compositions based on anticholinesterase drugs and on a steroid
10/24/2002	WO2002040015A8 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
10/24/2002	WO2002032397A9 Electroprocessing in drug delivery and cell encapsulation
10/24/2002	WO2002024610A3 Method for producing an antineoplastic
10/24/2002	WO2002000913A9 MODULATION OF β-AMYLOID LEVELS BY β-SECRETASE BACE2
10/24/2002	WO2002000210A3 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
10/24/2002	WO2001085206A3 Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound
10/24/2002	WO2001070210A3 Methods for improving size and appearance of a wound
10/24/2002	WO2001068135A9 Compositions and methods for affecting osteogenesis
10/24/2002	WO2001062793A9 Estrogen receptor beta variants and methods of detection thereof
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	WO2001055337A3 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
10/24/2002	US20020156585 Crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (S. aureus MurB)
10/24/2002	US20020156266 Sodium phosphate cotransporter expressed on apical surface of intestinal epithelial cells (huNpt2B) and polypeptides related thereto
10/24/2002	US20020156258 Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
10/24/2002	US20020156252 Novel Stra6 polypeptides
10/24/2002	US20020156150 Medical devices and applications of polyhydroxyalkanoate polymers
10/24/2002	US20020156129 Method of treating pruritus and a pharmaceutical composition for the method
10/24/2002	US20020156125 Coadministering an oral cyclosporin enhancing agent with paclitaxel or docetaxel
10/24/2002	US20020156124 Paclitaxel, a solvent, a surfactant, a substituted cellulosic polymer, and a P-glycoprotein inhibitor; supersaturation of a microemulsion upon contact with water
10/24/2002	US20020156122 Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
10/24/2002	US20020156091 Dosing interval of the nimesulide overlaps with that of the oxycodone to reduce the amount of oxycodone needed to provide an effect
10/24/2002	US20020156089 Use of CRF antagonists and related compositions
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156067 New drug combinations
10/24/2002	US20020156056 Fast-dispersing dosage form of apomorphine and testosterone that disintegrates in the oral cavity within 1-30 seconds
10/24/2002	US20020156055 Method of regulating the female reproductive system through angiogenesis inhibitors
10/24/2002	US20020156043 Methods of identifying optimal drug combinations and compositions thereof
10/24/2002	US20020156035 NET-4 is a member of the tetraspan transmembrane receptor family; antisense molecules, ribozymes, antibodies and antibody fragments for reductin NET-4 gene expression or activity; antitumor agents

1 ... 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 ... 1151